Peptide Monographs

Cagrilintide and Semaglutide side by side

Cagrilintide and Semaglutide are both indexed under Incretin receptor agonists. Every cell below carries the record it came from, and an axis with no retrieved value reads Unknown rather than being filled by inference.

Summary

The two are studied together as a co-administered combination, which is why they are searched together. Cagrilintide is a long-acting amylin analogue, per the cited 2021 Journal of Medicinal Chemistry paper, and semaglutide is a long-acting GLP-1 receptor agonist; the cited 2023 Lancet and 2025 New England Journal of Medicine papers report their co-administration.

[1, 2, 3, 4, 5]

Side by side

Curated comparison axes for Cagrilintide and Semaglutide
AxisCagrilintideSemaglutide
Reported mechanismA long-acting amylin analogue reported in the retrieved records to act at amylin and calcitonin family receptors, with brain amylin receptors 1 and 3 named in a 2025 record.[1, 9]Agonist at the glucagon-like peptide-1 receptor, the single-receptor mechanism of the incretin receptor agonist class.[20, 21] (derived value: Derived: the retrieved citation metadata for this compound does not state the receptor in a title. The receptor mechanism is taken from the cited 2024 GLP-1 receptor review, and this compound is placed in that class by the cited 2024 BMJ network meta-analysis of GLP-1 receptor agonists.)
Molecular formulaC194H312N54O59S2[6]C187H291N45O59[14]
Molecular weight4409 g/mol[6]4114 g/mol[14]
FDA application registerA query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[7]A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including NDA213051, marketed as OZEMPIC, RYBELSUS). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[15]

Where the two literatures diverge

Receptor target is the divergence: amylin receptors for cagrilintide, the GLP-1 receptor for semaglutide. The semaglutide literature includes the cited 2021 New England Journal of Medicine obesity trial as monotherapy and large cardiovascular outcome trials; the cagrilintide literature is almost entirely in combination with semaglutide. Semaglutide returned FDA application records under its generic name, recorded on its page; cagrilintide did not.

[1, 2, 3, 4, 5]

Where this page sits

Full pages: Cagrilintide and Semaglutide.

Shared class: Incretin receptor agonists.

Other pairs in the same class

All side-by-side pages: index.

Sources

  1. Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of medicinal chemistry (2021). pmid:34288673
  2. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet (London, England) (2023). pmid:37364590
  3. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine (2025). pmid:40544433
  4. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med (2021). pmid:33567185
  5. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med (2016). pmid:27633186
  6. PubChem Compound Summary for CID 171397054, Cagrilintide. PubChem, National Library of Medicine (2026). pubchem:171397054
  7. Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:cagrilintide
  8. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. The Journal of pharmacology and experimental therapeutics (2021). pmid:33727283
  9. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine (2025). pmid:40609154
  10. Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2022). pmid:36242844
  11. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet (London, England) (2021). pmid:34798060
  12. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet (London, England) (2021). pmid:33894838
  13. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England journal of medicine (2025). pmid:40544432
  14. PubChem Compound Summary for CID 56843331, Semaglutide. PubChem, National Library of Medicine (2026). pubchem:56843331
  15. Drugs@FDA application register query for this compound, 1 application(s) returned: NDA213051. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:semaglutide
  16. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med (2023). pmid:37952131
  17. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med (2021). pmid:33185364
  18. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med (2024). pmid:38785209
  19. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med (2021). pmid:34170647
  20. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther (2024). pmid:39289339
  21. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ (2024). pmid:38286487

On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.

Related resources